Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects.

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Abstract Text:

Susan L Ford,Ya-Chi Chen,Yu Lou,Julie Borland,Sherene S Min,Geoffrey J Yuen,Mark J Shelton,Susan L Ford,Ya-Chi Chen,Yu Lou,Julie Borland,Sherene S Min,Geoffrey J Yuen,Mark J Shelton,

Rifabutin (RFB) is administered for treatment of tuberculosis and Mycobacterium avium complex infection, including use for patients coinfected with human immunodeficiency virus (HIV). Increased systemic exposure to RFB and its equipotent active metabolite, 25-O-desacetyl-RFB (dAc-RFB), has been reported during concomitant administration of CYP3A4 inhibitors, including ritonavir (RTV), lopinavir, and amprenavir (APV); therefore, a reduction in the RFB dosage is recommended when it is coadministered with these protease inhibitors. Fosamprenavir (FPV), the phosphate ester prodrug of the HIV type 1 protease inhibitor APV, is administered either with or without RTV. A randomized, open-label, two-period, two-sequence, balanced, crossover drug interaction study was conducted with 22 healthy adult subjects to compare steady-state plasma RFB pharmacokinetic parameters during concomitant administration of FPV-RTV (700/100 mg twice a day [BID]) with a 75%-reduced RFB dose (150 mg every other day [QOD]) to the standard RFB regimen (300 mg once per day [QD]) by geometric least-squares mean ratios. Relative to results with RFB (300 mg QD), coadministration of dose-adjusted RFB with FPV-RTV resulted in an unchanged RFB area under the concentration-time curve for 0 to 48 h (AUC(0-48)) and a 14% decrease in the maximum concentration of drug in plasma (C(max)), whereas the AUC(0-48) and C(max) of dAc-RFB were increased by 11- and 6-fold, respectively, resulting in a 64% increase in the total antimycobacterial AUC(0-48). Relative to historical controls, the plasma APV AUC from 0 h to the end of the dosing interval (AUC(0-tau)) and C(max) were increased approximately 35%, and the concentration at the end of the dosing interval at steady state was unchanged following coadministration of RFB with FPV-RTV. The safety profile of the combination of RFB and FPV-RTV was consistent with previously described events with RFB or FPV-RTV alone. Based on the results of this study, a reduction in the RFB dose by >/=75% (to 150 mg QOD or three times per week) is recommended when it is coadministered with FPV-RTV (700/100 mg BID).

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Publishing Authors By Initials

SL Ford,YC Chen,Y Lou,J Borland,SS Min,GJ Yuen,MJ Shelton,SL Ford,YC Chen,Y Lou,J Borland,SS Min,GJ Yuen,MJ Shelton,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Antimicrobial agents and chemotherapy

VOLUME: 52

Page Numbers: 534-8

Journal Abbreviation: Antimicrob. Agents Chemother.

ISSN: 0066-4804

DAY: 3

MONTH: 12

YEAR: 2007

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 315061

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects.

AFFILIATION: GlaxoSmithKline CPDM, Five Moore Drive, RTP, NC 27709. susan.l.ford@gsk.com.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Antimicrob Agents Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects Related Publications

• Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
• Augmentation strategies to increase antidepressant efficacy.
• Bacteriorhodopsin optoelectronic synapses.
• Chronic sigmoid volvulus.
• Cognitive costs of exposure to racial prejudice.
• Cyproheptadine for pediatric intrathecal baclofen withdrawal: a case report.
• Eat smart and move more to combat arthritis.
• External auditory canal cholesteatoma: clinical and imaging spectrum.
• Factors affecting viability of fresh and frozen-thawed sheep demi-embryos.
• From dog to man: the broad spectrum of inflammatory myopathies.
• Imaging findings of cochlear nerve deficiency.
• In praise of real nurses.
• Inter-parental conflict and children's academic attainment: a longitudinal analysis.
• Non-pathogenic protein aggregates in skeletal muscle in MLF1 transgenic mice.
• Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects.
• Pityriasis rosea; report of three cases within one household.
• Primary jugular foramen meningioma: imaging appearance and differentiating features.
• Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.
• Reproductive response to suckling manipulation in Spanish goats.
• Reproductive safety of vaccination with Vista 5 L5 SQ near breeding time as determined by the effect on conception rates.
• Spiritual well-being, anxiety, and depression in antepartal women on bedrest.
• Sudden gains in cognitive therapy of depression and depression relapse/recurrence.
• THE UNDERSTANDING ASSISTANT.
• Ten myths and one truth about generalised HIV epidemics.
• The epidemiology of fractures in England.
• The molecular neurobiology of depression.
• Use of treatment algorithms for depression.
• Using mental health consultation to decrease disruptive behaviors in preschoolers: adapting an empirically-supported intervention.
• What's new in muscle and peripheral nerve diseases?
• [Use of silicone for relining and duplicating dentures]